LLY insider William Kaelin reports common stock acquisition on Form 4
Rhea-AI Filing Summary
Eli Lilly & Co director William G. Kaelin, Jr. reported an acquisition of company stock on a Form 4. On 11/17/2025, he acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. After this transaction, he beneficially owned a total of 21,836.814 Eli Lilly shares, held in direct ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 215.327 | $1,021.70 | $220K |
FAQ
What insider transaction did Eli Lilly (LLY) report on this Form 4?
The Form 4 reports that director William G. Kaelin, Jr. acquired 215.327 shares of Eli Lilly common stock in a single transaction.
On what date did the Eli Lilly (LLY) insider stock transaction occur?
The earliest transaction date reported is 11/17/2025, which is when the common stock acquisition took place.
What is the relationship of the reporting person to Eli Lilly (LLY)?
The reporting person, William G. Kaelin, Jr., is identified as a director of Eli Lilly & Co.
Is the Eli Lilly (LLY) Form 4 filed by one person or a group?
The Form 4 is indicated as being filed by one reporting person, not by a group.
What type of security did the Eli Lilly (LLY) insider acquire?
The insider acquired common stock of Eli Lilly & Co, reported in Table I for non-derivative securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.